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Absence of the CD1 Molecule Up-Regulates Antitumor Activity
Induced by CpG Oligodeoxynucleotides in Mice1
Lucia Sfondrini,* Dario Besusso,* Maria Teresa Zoia,* Monica Rodolfo,†
Anna Maria Invernizzi,* Masaru Taniguchi,§ Toshinori Nakayama,§ Mario Paolo Colombo,‡
Sylvie Me´nard,* and Andrea Balsari2¶
The role of NKT cells on antitumor activity of CpG oligodeoxynucleotides (ODNs) was evaluated by peritumoral injections of
CpG-ODNs in s.c. melanoma-bearing mice of strains differing in the number of NKT cells (athymic nude mice, recombination-
activating gene//transgenic V14/V8.2 mice that generate NKT cells; J281/ mice and CD1/ mice, which both have a
strongly reduced number of NKT cells; and C57BL/6 wild-type mice). Tumor growth was significantly inhibited in strains
enriched or depleted of NKT cells. The two murine strains having a reduced number of NKT cells differed significantly in the
CpG-dependent tumor growth inhibition: in J281/ mice this inhibition was superimposable to that observed in C57BL/6 mice,
while in CD1/ mice the inhibition was dramatic. The increased tumor inhibition in CD1/ correlated with a significantly higher
ratio of IFN--IL-4 production in response to CpG as compared with C57BL/6 and J281/ mice. Experiments in which
preparations of APCs and lymphocytes of the three strains were mixed showed that in the presence of APCs not expressing CD1,
the production of CpG-ODN-induced type 1 cytokines was higher. Phenotype analysis of IFN-- and IL-4-producing cells revealed
that the differences between CD1/ and C57BL/6 in the production of these two cytokines were mainly due to CD3 T lym-
phocytes. These data point to a regulatory role for the CD1 molecule in antitumor activity induced by danger signals, indepen-
dently of V14 NKT cells. The identification of a CD1-dependent suppressive subpopulation(s) might have important implications
for the study of tolerance in the context of cancer, autoimmunity, and transplantation. The Journal of Immunology, 2002, 169:
151–158.
B acterial DNA can activate the vertebrate immune systemthrough recognition of unmethylated cytosine-guanosinedinucleotides, i.e., CpG motifs, within a specific pattern
of flanking bases (1). Synthetic oligodeoxynucleotides (ODNs)3
containing CpG motifs also activate various immune cell subsets,
including macrophages and NK cells, when injected into mice (1,
2), and induce production of a wide variety of Th1-promoting cy-
tokines independently of any known antisense effect (1–5). Recent
studies have demonstrated the powerful adjuvant effect of CpG-
ODNs, which can be used to trigger protective and curative Th1
responses in vivo (3, 6–8). Indeed, promising results have been
reported in infectious diseases such as hepatitis B and Listeria (9,
10). ODNs have also been used as adjuvants for immunization
against tumor Ags (11, 12). Recently, an antitumor effect after
direct injection of ODNs in the area around neuroblastomas in
mice has been reported, sometimes leading to complete eradication
of the tumors (13). In that model, NK cells appeared to play a
critical role in the antitumor activity, consistent with the finding
that CpG-ODNs rapidly activate NK cells in vivo to display
lytic activity (14). Moreover, in a murine model of experimental
metastasis, activation of NK and NK-like NK1.1 T (NKT)
cells was reported to be critical in the CpG-induced antimeta-
static effect (15).
In vitro data suggest that NK cell activation is mediated by the
large amounts of IL-12 produced by CpG-activated APCs (14).
IL-12 also appears to induce lytic activity of NKT cells (16), al-
though it is unclear whether CpG-ODNs activate these cells. The
NKT subset, which expresses the NK1.1 Ag and intermediate lev-
els of TCR, represents a distinct and functionally important T cell
lineage (17–21). Most NKT cells use a limited TCR repertoire,
comprising an invariant V14-J281 chain paired preferentially to
V8.2 in mice (17–23) or the homologous invariant V24-JQ
chain paired to V11 in humans (24–27). Most murine NKT cells
are restricted by CD1d molecules (27), which resemble MHC class
I molecules structurally (28–30) and are expressed mainly on cells
of the different hemopoietic lineages (31–33). CD1d molecules are
also essential for the development of a major subset of NKT cells,
as demonstrated by studies using CD1d-deficient mice (34–36).
An important characteristic of NKT cells is their ability to rapidly
produce high levels of cytokines, especially IL-4 and IFN- (18).
Recent studies have revealed an active role for NKT cells in tumor
destruction in several tumor models in mice (16, 37), and the an-
titumor effect of the CD1d-binding ligand -galactosylceramide
(38), which specifically stimulates NKT cells, is being tested in
phase I clinical trials (39). In contrast, some studies indicate an
immunosuppressive function for NKT cells. This NKT activity has
been observed in UV-induced immune suppression (40) and in
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anterior chamber-associated immune deviation (41). Moreover, in
a mouse model in which tumors spontaneously regress after initial
growth and then recur, a negative regulation of tumor immuno-
surveillance by IL-13, possibly triggered by CD4NKT cells (42),
has been demonstrated.
Recent evidence indicates that the tumor surveillance activity of
NKT cells differs from that of NK cells (43). In some models, both
NK and NKT cells exert protective activity against tumor metas-
tasis or development, whereas in other settings NK cell-mediated
tumor rejection clearly does not require NKT cell activity (43).
To further define the role of NKT cells in the antitumor activity
induced by CpG motifs, we compared the therapeutic effect of
peritumoral injections of CpG-ODNs in athymic mice, wild-type
C57BL/6 mice, recombination-activating gene (RAG) knockout/
transgenic (tg) V14/V8.2 mice, CD1 knockout mice, and J281
knockout mice, which differ in the number of NKT cells. CpG-
ODN 1668, which has been demonstrated to activate immune cells
via Toll-like receptor 9, a family member of the phylogenetically
conserved receptors mediating innate immunity (44), has been
used in this study.
Materials and Methods
Cells
B16 murine melanoma cells were routinely cultured in DMEM supple-
mented with 10% FBS, glutamine, and antibiotics.
Oligonucleotides
Purified single-stranded phosphorothioated ODN 1668 (5-TCCATGA
CGTTCCTGATGCT-3) containing a CpG motif, and control ODN AP1
(5-GCTTGATGACTCAGCCGGAA) lacking a CpG motif (7) were syn-
thesized in endotoxin-free conditions by M-Medical-GENENCO (Firenze,
Italy). Phosphorothioate modification was used to reduce the susceptibility
of the ODN to DNase digestion and thereby significantly prolong its t1/2 in
vivo. Toxicity of ODNs on tumor cells was evaluated in sulforhodamine B
proliferation assay (45). Briefly, B16 cells were seeded at 1.5  103 cells/
well in 96-well microplates; ODNs at various concentrations (5  106,
5  107, or 5  108 M) were added at day 1 of culture, and tumor cell
growth was evaluated at day 3, as described (45). Tests were performed in
quadruplicate.
Mice
CD1.1 (CD1/) mice (36, 46) were kindly provided by G. Eberl (Ludwig
Institute for Cancer Research, Lausanne Branch, University of Lausanne,
Epalinges, Switzerland); RAG/ V14tgV8.2tg (NKT) mice (47) and
J281/ mice (16) were provided by M. Taniguchi (Chiba University,
Chiba, Japan); C57BL/6 mice and athymic (nude) mice were purchased
from Charles River (Calco, Italy). All mice were bred in the Istituto Na-
zionale Tumori (INT) animal facilities, and all studies were approved by
the INT Institutional Review Board.
In vivo experiments
Mice were inoculated with 8  105 B16 melanoma cells in the right flank,
and 10 days later, inoculated s.c. in the vicinity of the tumor with ODN
1668 or AP1 (40 g dissolved in 100 l saline) or with 100 l saline daily
for 5 days. Two perpendicular diameters of the tumor mass were measured
with a caliper every 2 days, and tumor volumes were calculated as: /6 
length width2. Differences between groups were analyzed using the two-
tailed unpaired t test and were considered significant at p  0.05.
ELISA and ELISPOT
Spleen cells were aseptically removed from C57BL/6, J281/, and
CD1/ mice. No difference in the total number of splenocyte population
was observed among the three murine strains. Spleen cells (107 spleno-
cytes) were cultured for 18 h in 24-well plates in 2 ml complete RPMI
supplemented with 10% defined FBS (10 Eu/ml endotoxin; HyClone,
Logan, UT) in the presence of serial dilutions of ODNs. Supernatants were
analyzed by ELISA (BD PharMingen, San Diego, CA) for IFN- and
IL-12 (p40 form) productions. IFN- and IL-12 production after in vivo
stimulation with ODNs was analyzed as above using spleen cell suspen-
sions prepared from mice injected i.v. with 200 g ODNs 90 min before
and incubated in 24-well plates (107 cells/well) for 18 h in complete RPMI
supplemented with 10% defined FBS.
IL-4 production after in vitro stimulation with ODNs was measured by
ELISPOT assay. Splenocytes (5  105 cells/well) were incubated in
MAHA nitrocellulose microtiter plates (Millipore, Bedford, MA) pre-
coated with 10 g/ml anti-mouse IL-4-coating Ab (Endogen, Woburn,
MA) in the presence of ODNs. After 24 h, plates were washed with PBS-
Tween 0.05%, incubated with 1 g/ml biotinylated anti-mouse IL-4 Ab
(Endogen) for 2 h, washed again, and incubated with alkaline phosphatase-
streptavidin diluted 1/1000 (Bio-Rad, Hercules, CA). Spots were devel-
oped with 5-bromo-4 chloro-3-indolyl phosphate in AMP substrate buffer
(Bio-Rad) and counted by an ELISPOT reader (AID, Gmbh Strassberg,
Germany).
Flow cytometry
Liver cells were isolated, as previously described (48). Briefly, total liver
cells were resuspended in 40% isotonic Percoll solution (Pharmacia Bio-
tech, Uppsala, Sweden) and underlaid with 80% isotonic Percoll solution.
Centrifugation for 20 min at 2000 rpm isolated the mononuclear cells at the
40–80% interface. The cells were washed twice with PBS containing 2%
FCS. Spleen or liver cells from C57BL/6, RAG/ V14tgV8.2tg,
CD1/, and J281/ mice were analyzed for NKT cell number by dou-
ble staining with FITC-conjugated anti-CD3 (145-2C11) and PE-conju-
gated anti-NK1.1 (PK136) Abs or with FITC-conjugated anti-DX5 and
biotin-conjugated anti-CD3 (145-2C11) Abs, followed by staining with
streptavidin-PE (BD PharMingen). To detect the percentage and phenotype
of cytokine-secreting cells after in vitro stimulation with ODNs, cells were
labeled for 5 min at a concentration of 107 cells/ml in ice-cold medium with
mouse IFN- or IL-4 catch reagent, an anti-IFN- or anti-IL-4 mAb con-
jugated to leukocyte cell surface-specific mAb (cytokine secretion assays;
Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were diluted with
medium to a final concentration of 105 cells/ml and incubated for 45 min
at 37°C. After the cytokine-capturing period, cells were harvested, resus-
pended at a concentration of 107 in PBS containing 0.5% BSA and 2 mM
EDTA, and stained for 10 min on ice with PE-conjugated anti-IFN- or
anti-IL-4 Ab (Miltenyi Biotec) and with FITC-conjugated anti-CD3 (145-
2C11), or anti-NK1.1 (PK136), or anti-CD4 (H129.19), or anti-CD8 (53-
6.7) (BD PharMingen). All Abs were used at concentrations recommended
by the manufacturer. Samples were analyzed by flow cytometry (FACS-
Calibur flow cytometer) and data analysis performed using CellQuest soft-
ware (BD Biosciences, Mountain View, CA).
Isolation and stimulation of MHC class II-positive and class
II-negative cells
Mouse MHC class II (Ia) microbeads (Miltenyi Biotec) were used for the
positive selection or depletion of APCs from spleen cells of C57BL/6 and
CD1/ mice, according to the manufacturer’s protocol. Briefly, cells were
magnetically labeled with the microbeads for 15 min at 4°C at a concen-
tration of 108 cells/ml, washed, resuspended in PBS (pH 7.2) supplemented
with 0.5% BSA, and passed through a separation MS column placed in
the magnetic field of a MACS separator (Miltenyi Biotec). Labeled and
unlabeled fractions, enriched or depleted of MHC class II cells, respec-
tively, were separately recovered and counted, and their purity was eval-
uated by FACScan analysis after staining with PE-conjugated anti-B220
(RA3-6B2) or anti-Mac1 (M1/70) Ab (BD PharMingen). MHC class II
and MHC class II cells obtained from C57BL/6, CD1/, and J281/
splenocytes were cultured for 18 h in 96-well plates in 0.15 ml complete
RPMI supplemented with 10% defined FBS in the presence of ODNs,
mixing (1:1) the two fractions obtained from cells of the three strains in
different combinations.
Results
Antitumor effects of CpG-ODNs in RAG/ V14tgV8.2tg mice
and athymic nude mice
Knockout tg RAG/ V14tgV8.2tg mice (B6 background) lack
the RAG and thus do not develop T or B cells. Moreover, RAG/
V14tgV8.2tg mice, unlike RAG/ mice, do not maintain de-
tectable levels of NK cells, probably because V8.2 expression
inhibits NK cell development and promotes NKT cell development
(47). Thus, RAG/ V14tgV8.2tg mice are rich only in NKT
lymphocytes. We tested the antitumor activity of CpG sequences
in these mice and in athymic nude mice (BALB/c background),
which lack T cells, but not NK cells. As a tumor model, we used
152 ROLE OF CD1 IN CpG-INDUCED ANTITUMOR ACTIVITY
 by guest on June 4, 2019
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
the poorly immunogenic B16 melanoma, a well-established mel-
anoma model in mice. The antitumor activity of CpG-ODN against
this melanoma has been reported to be NK cell dependent in athy-
mic mice (49). A total of 25 RAG/ V14tgV8.2tg mice and 29
nude mice was injected s.c. with 8  105 B16 melanoma cells.
Tumor growth was slightly faster in the athymic nude mice, and at
day 10 tumor nodules were measurable only in nude mice, al-
though tumors were palpable in all mice of both strains. Mice of
each strain were randomly divided into three groups and injected
at the tumor site on each of 5 days with CpG-ODN 1668, ODN
AP1 lacking the CpG motif (40 g/100 l saline daily), or with
saline. In both strains, treatment with CpG-ODN reduced tumor
growth as compared with treatment with control ODN AP1 or
saline (Fig. 1). By day 17 after tumor implantation, tumor volumes
in CpG-ODN-treated nude mice were 67% smaller than in saline-
treated nude mice (mean  SE: 659  132 mm3 vs 2025  266
mm3, p  0.0001) and 49% smaller than in the AP1 ODN-treated
group (659  131 mm3 vs 1296  195 mm3, p  0.01), while
RAG/ V14tgV8.2tg mice treated with CpG-ODN had 82%
smaller tumor volumes than their saline-treated counterparts
(mean SE: 247 67 mm3 vs 1355 266 mm3, p 0.0001) and
65% smaller than those that received ODN AP1 (247  67 mm3
vs 713  197 mm3, p  0.04). The antitumor activity of CpG-
ODNs did not appear to be mediated by a direct toxicity on tumor
cells because no growth inhibition was observed when CpG-ODN
at various concentrations was added to in vitro cultured melanoma
cells (data not shown).
Antitumor effects of CpG-ODN in C57BL/6 mice and in CD1/
and J281 chain/ knockout mice
Because both athymic and RAG/ V14tgV8.2tg mice lack T
cells and thus cannot provide information on a possible role for
NKT cells in shaping initial T cell activation in response to CpG
ODNs, we evaluated the antitumor growth effects of CpG-ODNs
in wild-type C57BL/6 mice as compared with two knockout
strains, homogeneous in genetic background and with markedly
reduced NKT cell numbers. C57BL/6 mice knocked out for CD1
or J281 have reduced numbers of NK1.1 T cells in the thymus,
spleen, bone marrow, and liver, but similar numbers of CD4,
CD8, and other lymphocytes to those in wild-type mice (34).
Consistent with previous data (21, 50), our multiparameter flow
cytometry analysis revealed a marked reduction, but not the ab-
sence of NKT cells in the spleen of these two knockout strains
(data not shown).
Mice of each strain were injected s.c. with B16 melanoma cells
(8  105/200 l). Ten days later, when tumor nodules were pal-
pable, mice of each strain were randomly divided into three groups
and injected at the tumor site with ODNs (40 g/100 l daily for
5 days) containing or lacking the CpG sequence, or with saline. A
superimposable growth rate of the tumors injected in the three
strains was observed after treatment with saline (Fig. 2). Tumor
growth was greatly reduced in all three strains of mice receiving
CpG-ODNs (Fig. 2), while slight tumor growth inhibition was ob-
served after treatment with control ODNs. By day 21 after tumor
implantation, tumor volumes in C57BL/6 mice injected with CpG-
ODNs were 75% smaller than in mice receiving saline (mean 
SE: 533  115 mm3 vs 2154  458 mm3, p  0.0009) and 54%
smaller than in control ODN-injected mice (533  115 mm3 vs
1162  319 mm3, p  0.05); J281/ mice receiving CpG-
ODNs had tumor volumes 75% smaller than in the saline-injected
group (mean  SE: 410  116 mm3 vs 1654  565 mm3, p 
0.04) and 71% smaller than in the control ODN group (410  116
mm3 vs 1396  422 mm3, p  0.04). CD1/ mice injected with
CpG-ODNs had tumors that were 98% smaller than the saline
group (mean  SE: 52  23 mm3 vs 2642  206 mm3, p 
0.0001) and 95% smaller than in the control ODN group (52  23
mm3 vs 1122  331 mm3, p  0.0046). The reduction in tumor
growth was significantly greater in CD1/ mice than in the other
two strains ( p  0.01 vs C57BL/6 and p  0.02 vs J281/).
Cytokine production after CpG-ODN stimulation
The immune response to CpG-containing ODNs is characterized
by production of Th1-promoting cytokines, especially IL-12 and
IFN- (2–4). IL-12 has been reported to induce a temporally se-
lective loss of CD3NK1.1 cells (48). We observed in C57BL/6
mice 24 h after injection of CpG-ODNs a strong depletion of liver
CD3NK1.1 cells, while the percentage of CD3DX5 cells
resulted in no modification (Fig. 3). To determine whether the
different antitumor responses observed in CD1/, J281/, and
C57BL/6 mice might reflect the differential production of these
regulatory cytokines in response to CpG-ODN stimulation, IL-12
and IFN- production in response to ODNs containing or lacking
FIGURE 1. Tumor volumes (mean  SE) in nude mice (A) and transgenic (V14tgV8.2tg) mice (B) treated 10 days after B16 melanoma cell injection
with saline (nude mice, n  5; V14tgV8.2tg mice, n  4), control ODN AP1 (nude mice, n  12; V14tgV8.2tg mice, n  11), or CpG-ODN 1668
(nude mice, n  12; V14tgV8.2tg mice, n  10) for 5 days (arrows) at the tumor site.
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a CpG sequence was evaluated by ELISA in the supernatant of
spleen cells from mice of the three strains incubated with different
doses of ODNs for 18 h. CpG-ODNs induced high level produc-
tion of IL-12 or IFN- in all three mouse strains, while no pro-
duction of either cytokine was detected in response to stimulation
with the control ODN, even at the highest concentration tested.
IL-12 levels were not significantly different in the three strains
(mean  SE: C57BL/6, 2291  149; CD1/, 1965  217;
J281/, 1540  338, at 1 g/ml ODN 1668), whereas CD1
knockout mice produced a significantly higher level of IFN- than
did the other two strains (Fig. 4A). Analysis of IL-12 and IFN-
production by splenocytes obtained 90 min after i.v. injection of
ODN (200 g) revealed production of these cytokines only with
ODN containing CpG sequences. These ex vivo data are consistent
with in vitro results, because despite the high variability among
individual mice, the CD1 knockout strain produced higher IFN-
levels compared with the other two strains (Fig. 4B), while a sim-
ilar production of IL-12 was observed (mean  SE: C57BL/6,
1876.8  245.1; CD1/, 1634.1  185.1; seven mice/group;
J281/ not evaluated). ELISA evaluation revealed no detect-
able IL-4 production in response to stimulation with ODNs in the
three strains after stimulation with CpG-ODN or control ODN.
However, in CD1/ splenocytes stimulated in vitro with CpG
ODN, the more sensitive ELISPOT assay revealed a significantly
FIGURE 3. FACS analysis of liver NKT cell population from C57BL/6
mice before (left) and 24 h after i.v. injection of 200 g ODN 1668 (right).
Liver cells were stained with FITC-conjugated anti-CD3 (x-axis) and PE-con-
jugated anti-NK1.1 (y-axis) Abs or with FITC-conjugated anti-DX5 (x-axis)
and biotin-conjugated anti-CD3 Abs plus streptavidin-PE (y-axis). For analy-
sis, live lymphocytes were gated according to light scatter properties and pro-
pidium iodide exclusion. One representative experiment of three is shown.
FIGURE 4. IFN- production in C57BL/6, J281/, and CD1/
mice after stimulation with CpG-ODN 1668 or control ODN AP1. A, Sin-
gle cell suspensions were prepared from spleens, placed in culture, and
stimulated with ODNs or not stimulated. Culture supernatants were har-
vested after 18 h, and IFN- levels were determined by ELISA. Data
(mean  SE) were pooled from two independent experiments, each per-
formed with four to five mice per group. , p  0.05 vs CD1/ mice by
two-tailed unpaired t test. B, Single cell suspensions were prepared from
spleens of mice 90 min after i.v. injection of 200 g ODNs. Culture su-
pernatants were harvested after 18 h, and IFN- levels were determined by
ELISA. Symbols represent the IFN- production by each single mouse;
horizontal lines represent the mean value in each group.
FIGURE 5. IL-4 production in C57BL/6, J281/, and CD1/ mice
after stimulation with CpG-ODN 1668 or control ODN AP1. Single cell sus-
pensions were prepared from mouse spleens and cultured in nitrocellulose
plates coated with anti-IL-4 Ab in the presence of ODNs. Spot number was
determined after 24 h of incubation. Data (mean SE) were pooled from two
independent experiments, each performed with four to five mice per group.
, p  0.05 vs CD1/ mice group by two-tailed unpaired t test.
FIGURE 2. Tumor volumes (mean  SE) in C57BL/6, J281/, and
CD1/ mice treated 10 days after B16 melanoma cell injection with saline
(C57BL/6 mice, n  10; J281/ mice, n  11; and CD1/ mice, n 
5), or CpG-ODN 1668 (C57BL/6 mice, n  13; J281/ mice, n  11;
and CD1/ mice, n  10) for 5 days (arrows) at the tumor site.
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lower number of cells ( p  0.05) producing IL-4 as compared
with the other two strains (Fig. 5).
The kinetics and magnitude of IFN- and IL-4 response in
C57BL/6 and CD1/ mice were evaluated using a new sorting
technique based on the surface capture of secreted cytokines by
bispecific Ab-Ab conjugates, which bind to IL-4 or IFN- and to
murine CD45, a highly abundant leukocyte cell surface protein
(51). FACScan analysis of C57BL/6 and CD1/ spleen cells in-
cubated with CpG-ODN or control ODN for different times re-
vealed similar kinetics of IFN- release induced by CpG-ODN in
the two strains, but a significantly higher number of cells secreting
IFN- in CD1/ than in C57BL/6 mice ( p  0.04) (Fig. 6). In
contrast, the number of cells producing IL-4 was significantly
higher in C57BL/6 mice ( p  0.02) (Fig. 6).
Role of APC on CpG-ODN-induced IFN- production
The regulatory role of APC expressing or not expressing CD1 on
the CpG-ODN-induced IFN- production was then evaluated.
Spleen cells from the three strains (C57BL/6, J281/, and
CD1/) were separated into MHC class II and MHC class II
fractions using MHC class II microbeads, and the positive frac-
tions containing APCs were mixed with the negative fractions con-
taining the lymphocytes. After stimulation with CpG-ODNs, the
production of IFN- and IL-4 was evaluated by ELISA. No de-
tectable levels of IL-4 were revealed in supernatants of any of the
fractions obtained from the three strains (not shown).
Increased production of IFN- by cells present in the MHC class
II fractions from C57BL/6 or J281/ mice in response to
CpG-ODN was observed when syngeneic APC were replaced with
APC-containing fractions obtained from CD1/ mice ( p  0.05
vs each syngeneic combination) (Fig. 7). In contrast, IFN- pro-
duction by the lymphocyte-containing fraction from CD1/ mice
was not significantly modified when syngeneic CD1/ APC were
replaced with APCs from C57BL/6 or J281/ mice.
In agreement with Warren et al. (52), who found no direct effect
of CpG-ODNs on purified T cells in vitro, no IFN- production
was observed by purified MHC class II-negative fractions (Fig. 7).
Phenotype of cells secreting IFN- and IL-4 in response to CpG
ODNs in C57BL/6 and CD1/ mice
To characterize the phenotype of spleen cells secreting IFN- and
IL-4 in response to CpG-ODN in C57BL/6 and CD1/ mice, a
multiparametric analysis using the capturing cytokine-bispecific
Ab and specific mAbs directed against CD3 and NK1.1 molecules
was performed. CpG-ODN stimulation induced IFN- secretion
from both CD3 cells and NK1.1 cells (Fig. 8). A significantly
higher number of CD3 T lymphocytes, secreting IFN- in re-
sponse to CpG-ODN, was detectable in CD1/ mice as compared
with C57BL/6 mice (49.4 vs 12.2%, p  0.006). Both CD8 and
CD4 populations were found to contribute to the increased pro-
duction of IFN- observed in CD1/ mice. No significant dif-
ferences in the number of NK1.1 cells secreting IFN- were de-
tectable between the two strains (1.9% in CD1/ vs 1.3% in
C57BL/6, p  0.55).
The CD3 T lymphocytes were found to be the major source of
the increased production of IL-4 in C57BL/6 mice as compared
with CD1/ mice (8.1 vs 2.2%, p  0.04) (Fig. 8). Very
few NK1.1 cells secreting IL-4 were observed in both strains
after CpG-ODN stimulation (0.05% in C57BL/6 and 0.09% in
CD1/). Therefore, the phenotype analysis of IFN-- and IL-4-
producing cells revealed that the differences between CD1/ and
C57BL/6 in the production of these two cytokines were mainly due
to CD3 T lymphocytes.
Discussion
Our data indicate that direct injection of CpG-ODNs in the peritu-
moral area represents a simple means of achieving immunotherapeu-
tic effects against B16 melanoma without the need for selection and
purification of tumor Ags. It is noteworthy that the CpG-ODN effect
FIGURE 6. Kinetics of activation of IFN-
(A)- and IL-4-producing (B) cells by ODN 1668
and control ODN AP1 (1 M for IFN-, 8 M
for IL-4). Single cell suspensions were prepared
from spleens, placed in culture, and stimulated
with ODNs. At the time points indicated, cells
were labeled with IFN- or IL-4 catch reagent,
allowed to secrete cytokines for 45 min at 37°C,
and stained with PE-conjugated anti-IFN- or
anti-IL-4 Ab. For FACScan analysis, live lym-
phocytes were gated according to light scatter
properties (forward and side scatter) and pro-
pidium iodide exclusion.
FIGURE 7. IFN- production after culture for 18 h in the presence of
CpG-ODN 1668 (1 M) by the APC-containing MHCII fraction or lym-
phocyte-containing MHCII fraction obtained from C57BL/6, J281/,
and CD1/ mice, or after coculture of the two fractions (1:1) in the dif-
ferent combinations from the three strains. The experiment reported is rep-
resentative of four independent experiments. , p 0.05 vs each syngeneic
combination by two-tailed unpaired t test.
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was observed in nonpathogen-free mice, and the tumor growth rate in
all B6 background strains (RAG/ V14tgV8.2tg, J281/,
CD1/, and C57BL/6) treated with saline was superimposable. The
slight inhibition of tumor growth in all strains by the control ODN
most likely rests in the presence of the phosphorothioate modification
(14, 53, 54).
The antitumor responses observed in immunologically different
strains might reflect the ability of CpG-ODNs to activate various
immune cell subsets. RAG/ V14tgV8.2tg mice, in which NK
cells are undetectable, but which are rich in NKT cells, respond
similarly to athymic mice in which the anti-B16 cell activity of
CpG-ODN is reportedly NK cell dependent (49). These results
suggest that NKT cells, like the NK cells in nude mice, in an
immune context expressing high level of these cells, can mediate
the antitumor activity induced by CpG-ODNs. Accordingly, treat-
ment of C57BL/6 with anti-NK1.1 Abs abrogated by 61% the an-
titumor activity of CpG-ODNs (data not shown). However, NKT
cells may be sufficient, but not necessary, on CpG-induced anti-
tumor activity because superimposable antitumor responses were
observed in C57BL/6 and J281/ mice, which partially lack
NKT cells. Moreover, it has been suggested that NKT cells may
represent a regulatory arm of the T cell response (21, 40, 55); the
similar inhibition of tumor growth observed in wild-type C57BL/6
mice and J281/ mice provides evidence against a regulatory
role for V14 NKT cells in shaping the CpG-induced antitumor
immune response.
The stronger antitumor response and the increased ratio of IFN-
-IL-4 in CD1/ mice as compared with C57BL/6 wild-type
mice are consistent with the data of Terabe et al. (42), obtained
using a mouse model in which the tumor shows a growth regres-
sion-recurrence pattern. In that study, increased resistance to tumor
recurrence was detected in CD1/ mice, with decreased IL-4 and
IL-13 production and increased IFN- production. The authors hy-
pothesized that because NKT cells represent a source of IL-4 and
IL-13, loss of this subpopulation, which might play a critical role
in down-regulation of tumor immunosurveillance, might account
for the resistance to tumor recurrence in CD1/ mice. Data on
J281/ mice indicate that, in our model, the greater tumor-pro-
tective response in CD1/ mice is not directly dependent on the
loss of V14 NKT cells. Moreover, in agreement with in vivo
antitumor response, we observed no increase of IFN- production
in response to CpG-ODNs from C57BL/6 spleen cells depleted of
FIGURE 8. Phenotypic analysis of IFN-- and IL-4-producing cells after 24 h of incubation with ODN 1668 or control ODN AP1 (1 M for IFN-,
8 M for IL-4). Cells were labeled with IFN- or IL-4 catch reagent, allowed to secrete cytokines for 45 min at 37°C, and stained with PE-conjugated Abs
against IFN- or IL-4 (y-axis) and with FITC-conjugated Abs against CD3 or CD4 or CD8 or NK1.1 (x-axis). For analysis, live lymphocytes were gated
according to light scatter properties and propidium iodide exclusion. One representative experiment of three is shown.
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NKT cells (CD3DX5) using anti-DX5-coated microbeads (data
not shown).
Recently, Dao et al. (56) reported that the impairment of pe-
ripheral deletion of T cells induced by anti-CD3 Ab in CD1/
mice (on the B6  129 background) is independent of V14 NKT
cells, because neither 2-microglobulin-deficient mice nor J281-
deficient mice reproduce the abnormality found in CD1/ mice.
As proposed by Dao et al. (56), it is possible to hypothesize the
presence of T cells that, interacting with CD1 expressed on APC,
negatively regulate the immune response. This hypothesis explains
the increased IFN- production by lymphocytes from C57BL/6
and J281/ mice in response to CpG-ODNs observed when
syngeneic APCs were replaced with CD1/ APCs. The develop-
ment of these suppressive T cells might be CD1 dependent because
the IFN- production by lymphocytes from CD1/ mice in the
presence of C57BL/6 and J281/ APCs was not significantly
different from that observed in the presence of syngeneic APCs. As
alternative hypothesis, as suggested by data of Chang et al. (57),
CD1 might negatively regulate immune response through interac-
tion with a CD1-specific inhibitory receptor(s) that could have a
broader cellular distribution that includes T cells. At the present
time, we do not know the CD1-reactive cell subset(s) involved in
the down-regulation of CpG-induced immune response because
besides V14 NKT cells, non-V14 NKT cells (55) and NK1.1
T cells also were reported to be dependent on CD1 for function
and/or development (30, 58–60).
Attempts to demonstrate a direct role for CD1 on APCs using a
mAb against CD1 both in vitro and in vivo (anti-CD1 mAb in-
jected into the tumor site for 5 days, starting 6 h before CpG ODN
injection) were not successful (not shown). However, considering
that blocking of CD1 activity with the Ab has been proven only in
vitro (61), these data cannot be considered conclusive.
Together, our data point to a regulatory role for CD1 in the
antitumor response induced by CpG danger signals independently
of V14 NKT cell activity. The increased antitumor activity in
response to CpG-ODN treatment in CD1/ mice compared with
C57BL/6 and J281/ mice appears to be related to the enhanced
IFN--IL-4 ratio produced in these mice, which affects the Th1/
Th2 differentiation process, and in turn might reflect the regulatory
role of CD1-restricted lymphocyte subset. Further analyses will
provide information about the immunological functions and the
ligand specificity of these CD1-dependent subpopulations. A num-
ber of recently described regulatory or suppressor T cell subsets
represent potentially formidable barriers to successful antitumor
immune responses (62–64). It may be that successful immuno-
therapies will require inclusion of strategies to interfere with the
action of suppressor or regulatory cells, possibly by transiently
depleting these cells or inhibiting their effector molecules. This
approach may be a key requirement for promoting tumor rejection.
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